MARROW GRAFT REJECTION AND VENO-OCCLUSIVE DISEASE OF THE LIVER IN PATIENTS WITH APLASTIC ANEMIA CONDITIONED WITH CYCLOPHOSPHAMIDE AND CYCLOSPORINE

Abstract

Based on studies in multiply transfused dogs showing that cyclosporine (CsA) pregrafting reduced the incidence of rejection, we treated 11 multiply transfused patients with severe aplastic anemia with CsA, 12.5–20 mg/kg/day i.m. on days-6 to-1, and cyclophosphamide, 50 mg/kg/day i.v. on days −5 to −2, followed on day 0 by a marrow graft from an HLA-identical sibling donor. Patients were not given additional infusions of buffy coat cells from their marrow donors. As postgrafting prophylaxia for graft-versus-host disease 10 patients were give CsA, 12.5 mg/kg/day orally, and one patient was given a standard regimen of intermittent method